cancerresearch

$MRNA.US $MRNAon
#莫德纳股价涨超12% #CancerResearch
Overnight, its market value surged by $44.5 billion, and its share price skyrocketed 177% in a single day—this isn’t just meme-stock hype. It’s the real story played out by US biotech firm Moderna on August 19.
What sparked this capital frenzy was a buzzword that has thrilled countless people: the success of a Phase 3 clinical trial for an mRNA cancer vaccine. The first of its kind.
Musk then commented on the social platform: "mRNA technology turns curing diseases into a software problem."
It sounds like the opening of a sci‑fi movie. But don’t get too excited yet—we’ll break it down piece by piece.